Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis
- Conditions
- Keratonjunctivitis
- Interventions
- Drug: topical steroids and cyclosporin-A
- Registration Number
- NCT04451239
- Lead Sponsor
- Ameera Gamal Abdelhameed
- Brief Summary
To explore the feasibility of combined topical corticosteroid and topical cyclosporine-A in COVID-19 patients with acute keratoconjunctivitis.
- Detailed Description
COVID-19 patients presenting with acute keratoconjunctivitis will be treated with Topical 1% prednisolone acetate fourTimes daily for 7 days as initial treatment, non-preserved artificial tears four times daily and cyclosporin A 0.5% four times daily .
Twelve patients with COVID-19 Keratoconjunctivitis will be enrolled in this open-label study. Symptoms and findings of the patients before and after treatment were recorded.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 12
- COVID-19 Patients with keratoconjunctivitis
- associated ocular pathology or disease
- other causes of keratoconjunctivitis for example allergic or herpetic
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description COVID-19 keratoconjunctivitis topical steroids and cyclosporin-A cases will receive topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .
- Primary Outcome Measures
Name Time Method Symptom improvement 10-15 days eye itching, foreign body sensation, tearing, redness in the eye and eyelid swelling
Signs improvement 10-15 days conjunctival injection, discharge, presence of superficial punctate keratitis (SPK), pseudomembranes on tarsal conjunctiva
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Farawanyia hospital
🇰🇼Kuwait, Farawanyia, Kuwait